Oruka Q2 net loss $41.2M; EVERLAST-A 63.5% PASI 100; cash $1.1B

Oruka Therapeutics, Inc.

Q2 2026 net loss $41.2M vs $24.6M in Q2 2025; R&D spend $43.3M; cash $1.1B funds through BLA filing.
EVERLAST-A Phase 2a: 40/63 (63.5%) achieved PASI 100 at Week 16; PASI 90 83%; IGA 0/1 84%.
EVERLAST-B fully enrolled (187 subjects); Week 16 data expected Q4 2026; Phase 3 for ORKA-001 in 1H 2027.
ORCA-SPLASH Phase 2 in HS initiated (~160 patients); ORKA-004 TL1A antibody enters clinic Q4 2026.
May 2026: IL-23 license with Paragon amended to include all therapeutic areas incl. IBD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.